Astrana Health Named to the 2026 Fortune 1000 List Following Strong Revenue Growth
StockNews.AI · 2 hours
AI Summary
Astrana Health was named to the Fortune 1000 for 2026, marking its debut on the ranking of the largest U.S. companies by revenue. In fiscal 2025, revenue reached $3.18 billion, up 56% YoY, with $205.4 million in adjusted EBITDA and $104.5 million of free cash flow. The milestone could attract growth-focused investors and support a near-term re-rating of its scale and AI-enabled platform.
Sentiment Rationale
Milestone recognition can boost investor perception of ASTH's growth trajectory and scalability, potentially leading to short-term upside; long-term impact depends on sustained fundamentals and execution.
Trading Thesis
Positive near-term catalyst; expect modest stock reaction over the next 1–3 quarters as investors value scale and AI-enabled care.
Market-Moving
- Fortune 1000 debut may draw near-term investor attention to ASTH.
- 2025 revenue growth supports a stronger growth narrative.
- EBITDA and FCF demonstrate cash generation and profitability momentum.
- Large provider network and patient base underline scalable care model.
Key Facts
- Astrana Health named to Fortune 1000 for 2026, debut on the list.
- FY2025 revenue: $3.18B, up 56% YoY; adjusted EBITDA $205.4M; FCF $104.5M.
- 20,000+ providers and ~1.55M patients in value-based care networks.
- AI-enabled, physician-centric care model emphasizes scalable outcomes and access.
- Milestone could attract growth-focused investors and modest near-term re-rating.
Companies Mentioned
- Astrana Health, Inc. (ASTH): Debut on Fortune 1000 highlights scale; AI-enabled, physician-centric model supports growth outlook.
- Fortune Magazine (N/A): Publishes Fortune 1000 rankings; provides third-party validation though not a publicly traded entity.
Corporate Developments
Category: Corporate Developments. This PR centers on a recognition milestone rather than earnings or M&A, signaling credibility and scale expansion for ASTH in AI-enabled care.